These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 7705494)

  • 101. Measles in developing countries. Part II. The predicted impact of mass vaccination.
    McLean AR; Anderson RM
    Epidemiol Infect; 1988 Jun; 100(3):419-42. PubMed ID: 3378585
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Measles antibodies and herd immunity in 20- and 40-year-old Norwegians.
    Flugsrud LB; Rłd TO; Aasen S; Berdal BP
    Scand J Infect Dis; 1997; 29(2):137-40. PubMed ID: 9181648
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Measles: what you can do.
    Davies N
    Br J Nurs; 2018 Feb; 27(3):116. PubMed ID: 29412035
    [No Abstract]   [Full Text] [Related]  

  • 104. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales.
    Pitman RJ; White LJ; Sculpher M
    Vaccine; 2012 Feb; 30(6):1208-24. PubMed ID: 22178725
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among children.
    Liu Y; Lu P; Hu Y; Wang Z; Deng X; Ma F; Tao H; Jia C; Ding X; Yang H; Liu P; Min J
    PLoS One; 2013; 8(6):e66771. PubMed ID: 23825562
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Reconstruction of measles dynamics in a vaccinated population.
    Wallinga J; Teunis P; Kretzschmar M
    Vaccine; 2003 Jun; 21(19-20):2643-50. PubMed ID: 12744901
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Measles in France: the epidemiological impact of suboptimal immunisation coverage.
    Bonmarin I; Levy-Bruhl D
    Euro Surveill; 2002 Apr; 7(4):55-60. PubMed ID: 12631938
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Measles in the 1980s.
    Christopher PJ; MacDonald PA; Murphy AM; Buckley PR
    Med J Aust; 1983 Nov; 2(10):488-91. PubMed ID: 6633361
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Difficulties in measles elimination: prevalence of measles antibodies before and after mass vaccination campaign in Laos.
    Kuroiwa C; Xayyavong P; Vongphrachanh P; Khampapongpane B; Yamanaka M; Nakamura S
    Vaccine; 2003 Jan; 21(5-6):479-84. PubMed ID: 12531647
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Measles elimination in Italy: projected impact of the National Elimination Plan.
    Manfredi P; Williams JR; Ciofi Degli Atti ML; Salmaso S
    Epidemiol Infect; 2005 Feb; 133(1):87-97. PubMed ID: 15724715
    [TBL] [Abstract][Full Text] [Related]  

  • 111. The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium).
    Beutels P; Van Damme P; Van Casteren V; Gay NJ; De Schrijver K; Meheus A
    Vaccine; 2002 Oct; 20(29-30):3551-9. PubMed ID: 12297401
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Measles seroprevalence in Izmir with special emphasis on measles vaccination policy for Turkey.
    Egemen A; Aksit S; Ozacar T; Kurugol Z; Keskinoglu P; Pehlivan T; Mutlu S
    Pediatr Int; 2001 Aug; 43(4):379-84. PubMed ID: 11472583
    [TBL] [Abstract][Full Text] [Related]  

  • 113. A secondary school outbreak of mumps following the childhood immunization programme in England and Wales.
    Wehner H; Morris R; Logan M; Hunt D; Jin L; Stuart J; Cartwright K
    Epidemiol Infect; 2000 Feb; 124(1):131-6. PubMed ID: 10722140
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Measles immunity over two decades in two large Italian Regions: How far is the elimination goal?
    Marchi S; Remarque EJ; Viviani S; Rizzo C; Monteverde Spencer GT; Coluccio R; Montomoli E; Trombetta CM
    Vaccine; 2021 Sep; 39(40):5928-5933. PubMed ID: 34456073
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage.
    van den Hof S; Berbers GA; de Melker HE; Conyn-van Spaendonck MA
    Vaccine; 1999 Dec; 18(9-10):931-40. PubMed ID: 10580207
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Estimation of measles reproduction ratios and prospects for elimination of measles by vaccination in some Western European countries.
    Wallinga J; Lévy-Bruhl D; Gay NJ; Wachmann CH
    Epidemiol Infect; 2001 Oct; 127(2):281-95. PubMed ID: 11693506
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Risk factors for measles virus infection and susceptibility in persons aged 15 years and older in China: A multi-site case-control study, 2012-2013.
    Ma C; Hao L; Rodewald L; An Q; Wannemuehler KA; Su Q; An Z; Quick L; Liu Y; Yan R; Liu X; Zhang Y; Yu W; Zhang X; Wang H; Cairns L; Luo H; Gregory CJ
    Vaccine; 2020 Apr; 38(16):3210-3217. PubMed ID: 32173094
    [TBL] [Abstract][Full Text] [Related]  

  • 118. An age-structured model of pre- and post-vaccination measles transmission.
    Schenzle D
    IMA J Math Appl Med Biol; 1984; 1(2):169-91. PubMed ID: 6600102
    [TBL] [Abstract][Full Text] [Related]  

  • 119. The use of the screening technique as a method of rapidly estimating vaccine efficacy.
    Hatton P
    Public Health; 1990 Jan; 104(1):21-5. PubMed ID: 2359815
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Oscillatory fluctuations in the incidence of infectious disease and the impact of vaccination: time series analysis.
    Anderson RM; Grenfell BT; May RM
    J Hyg (Lond); 1984 Dec; 93(3):587-608. PubMed ID: 6512259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.